Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash. The ...

Opdivo (nivolumab) is a brand-name drug that’s prescribed for certain types of cancer. Opdivo isn’t known to interact with other medications. Opdivo is prescribed to adults for treating ...

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales. In final guidance ...

Treatment with nivolumab reduced the risk of disease recurrence, progression or death by 42% compared with placebo. The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with ...

Last week’s NICE rejection of Opdivo for routine use in lung cancer patients has presented BMS with another setback – and an opportunity for Merck Sharp & Dohme (Merck in the US) and its rival ...

Nivolumab (branded as Opdivo) - will be free from 1 November for eligible people with kidney cancer. Director of pharmaceuticals Geraldine MacGibbon said the drug-funding agency was pleased to ...

Among patients with advanced melanoma, treatment with Opdivo (nivolumab) with or without Yervoy (ipilimumab) benefited both overall survival (OS, the time a patient lives, regardless of disease status ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo. Opdivo (nivolumab) with Abraxane (nab-paclitaxel) could expand the therapeutic ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...

An FDA Advisory Committee on Thursday voted against broader use of immune checkpoint inhibitors Keytruda and Opdivo developed by Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) in certain ...

The story — and the transformative impact — of Bristol Myers Squibb’s Opdivo and Merck’s Keytruda are well known at this point. Yet the field has also been in a moment of commemoration ...

September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...